Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...

A major European clinical research event in oncology gives a boost to antibody–drug conjugates, treatments that work like a Trojan horse, delivering chemotherapy to the interior of malignant cells ...

GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).

(Alliance News) - GSK PLC on Monday announced an agreement with Syndivia that grants GSK exclusive worldwide rights to develop and commercialise a preclinical antibody-drug conjugate for metastatic ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.